Evidence map›Paper›PMID 41661403›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Characterization of immune landscape and prognostic value of IL-17-related signature in uterine corpus endometrial carcinoma.

Man Yu, Pei Wang, Rui Liu, Min Li

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Man YuChinese Medicine Centre, Beijing Luhe Hospital Capital Medical University, No. 82, Xinhua South Road, Tongzhou District, Beijing, 101100, China.
Pei WangChinese Medicine Centre, Beijing Luhe Hospital Capital Medical University, No. 82, Xinhua South Road, Tongzhou District, Beijing, 101100, China.
Rui LiuChinese Medicine Centre, Beijing Luhe Hospital Capital Medical University, No. 82, Xinhua South Road, Tongzhou District, Beijing, 101100, China.
Min LiChinese Medicine Centre, Beijing Luhe Hospital Capital Medical University, No. 82, Xinhua South Road, Tongzhou District, Beijing, 101100, China. MinLi0527@163.com.ORCID http://orcid.org/0009-0000-1966-8754

Funding

the Capital's Funds for Health Improvement and Research 2024-2-7082
6 · The paper itself

Abstract

backgroundInterleukin-17 (IL-17) plays a crucial role in the development of uterine corpus endometrial carcinoma (UCEC), but its prognostic and therapeutic implications remain unclear. This study aimed to investigate IL-17-related gene signatures and their potential as prognostic markers and therapeutic targets in UCEC.

resultsWe developed a prognostic model based on four IL-17-related genes (SCGB1D2, SST, SELENOP, TMTC1) that predicted overall survival in UCEC. High-risk scores were associated with poorer survival outcomes and an immunosuppressive tumor microenvironment. In contrast, low-risk scores correlated with immune checkpoint upregulation and higher sensitivity to immune checkpoint blockade (ICB). Immunohistochemistry confirmed the upregulation of SCGB1D2 in UCEC tissues.

conclusionThis IL-17-based prognostic model offers new insights into UCEC risk stratification and potential immunotherapeutic strategies. It highlights the clinical relevance of IL-17 signaling in personalized treatment approaches.

Indexed as

Endometrial NeoplasmsInterleukin-17Tumor MicroenvironmentBiomarkers, TumorFemaleHumansMiddle AgedPrognosisBiomarkers, TumorInterleukin-17Endometrioid cancerImmune microenvironmentInterleukin 17 (IL-17)PrognosisTumor microenvironment

Identifiers

PMID41661403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.